Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

The efficient engraftment in immune-deficient mice achieved with both acute lymphoblastic leukemia (ALL) cell lines and primary samples has facilitated identification of the antileukemia activity of a wide variety of agents. Despite widespread usage, however, little is known about the early ALL localization and engraftment kinetics in this model, limiting experimental read-outs primarily to survival and endpoint analysis at high disease burden. In this study, we report that bioluminescent imaging can be reproducibly achieved with primary human ALL samples. This approach provides a noninvasive, longitudinal measure of leukemia burden and localization that enhances the sensitivity of treatment response detection and provides greater insight into the mechanism of action of antileukemia agents. In addition, this study reveals significant cell line- and species-related differences in leukemia migration, especially early in expansion, which may confound observations between various leukemia models. Overall, this study demonstrates that the use of bioluminescent primary ALL allows the detection and quantitation of treatment effects at earlier, previously unquantifiable disease burdens and thus provides the means to standardize and expedite the evaluation of anti-ALL activity in preclinical xenograft studies.

[1]  Robin S. Dothager,et al.  Advances in bioluminescence imaging of live animal models. , 2009, Current opinion in biotechnology.

[2]  T. Rosol,et al.  A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma. , 2007, Cancer research.

[3]  B. Schäfer,et al.  Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. , 2010, The Journal of clinical investigation.

[4]  Levi Garraway,et al.  SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines , 2008, Nucleic acids research.

[5]  B. Levine,et al.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. , 2010, Cancer research.

[6]  J A Thomson,et al.  Short tandem repeat profiling provides an international reference standard for human cell lines , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  James R. Downing,et al.  Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells , 2011, Nature.

[8]  J. Falkenburg,et al.  Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. , 2001, Experimental Hematology.

[9]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[10]  Francois Lassailly,et al.  "Microenvironmental contaminations" induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. , 2010, Blood.

[11]  P. Pandolfi,et al.  Modelling haematopoietic malignancies in the mouse and therapeutical implications , 2002, Oncogene.

[12]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[13]  Joseph Zeidner,et al.  The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.

[14]  Adrian Saldanha,et al.  Structural basis for the spectral difference in luciferase bioluminescence , 2006, Nature.

[15]  H. Kestler,et al.  Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. , 2011, Cancer cell.

[16]  C. Contag,et al.  Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. , 2005, Journal of biomedical optics.

[17]  J. D. Funkhouser,et al.  Cancer susceptibility in ataxia-telangiectasia. , 1992, Leukemia.

[18]  J. Medin,et al.  Anti-Leukemia Activity of In Vitro-Expanded Human Gamma Delta T Cells in a Xenogeneic Ph+ Leukemia Model , 2011, PloS one.

[19]  R. Lock,et al.  The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. , 2002, Blood.

[20]  V. Brown,et al.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Weinberg,et al.  Gene delivery to human B-precursor acute lymphoblastic leukemia cells. , 1998, Blood.

[22]  B. Rice,et al.  Three-dimensional reconstruction of in vivo bioluminescent sources based on multispectral imaging. , 2007, Journal of biomedical optics.

[23]  R. Lock,et al.  Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. , 2004, Blood.

[24]  O. Kollet,et al.  Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis , 1997, Journal of Molecular Medicine.

[25]  F. Sigaux,et al.  Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse , 2011 .

[26]  J. Downing,et al.  Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells , 2011, Nature.

[27]  Yusuke Inoue,et al.  Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy. , 2007, Experimental hematology.

[28]  D. Teachey,et al.  The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. , 2006, Blood.

[29]  B. Lange,et al.  Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. , 1991, Blood.

[30]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[31]  R. Hardy,et al.  The fetal origin of B-precursor leukemia in the E-mu-ret mouse. , 1998, Blood.

[32]  Yusuke Inoue,et al.  Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model. , 2008, Experimental hematology.

[33]  D. Campana,et al.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  J. Falkenburg,et al.  A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. , 2010, Blood.

[35]  I. Fichtner,et al.  CHILDHOOD ALL BLASTS RETAIN PHENOTYPIC AND GENOTYPIC CHARACTERISTICS UPON LONG-TERM SERIAL PASSAGE IN NOD/SCID MICE , 2000, Pediatric hematology and oncology.

[36]  J. Dipersio,et al.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. , 2007, Experimental hematology.

[37]  K. Weinberg,et al.  Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. , 2000, Blood.

[38]  J. Dick,et al.  Differential kinetics of engraftment and induction of CD10 on human pre-B leukemia cell lines in immune deficient scid mice. , 1992, Leukemia.

[39]  C. Rübe,et al.  Good Engraftment of B-Cell Precursor ALL in NOD-SCID Mice , 1997, Klinische Padiatrie.

[40]  R. Hardy,et al.  The evolution of B precursor leukemia in the Emu-ret mouse. , 1998, Blood.

[41]  J. Tchinda,et al.  Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. , 2011, Blood.

[42]  Christopher H Contag,et al.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. , 2003, Blood.

[43]  U. Kees,et al.  Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia , 2010, BMC Genomics.

[44]  C. Contag,et al.  Advances in in vivo bioluminescence imaging of gene expression. , 2002, Annual review of biomedical engineering.

[45]  D. Teachey,et al.  In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. , 2006, Blood.

[46]  William M Gallagher,et al.  Bioluminescent imaging: a critical tool in pre‐clinical oncology research , 2010, The Journal of pathology.

[47]  J. Falkenburg,et al.  An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. , 2002, Blood.

[48]  M. Introna,et al.  Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells. , 2001, Haematologica.

[49]  D. Teachey,et al.  mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. , 2008, Blood.

[50]  Ash A. Alizadeh,et al.  Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. , 2011, Cancer research.

[51]  F. Uckun,et al.  Selective homing of human leukemic B-cell precursors to specific lymphohematopoietic microenvironments in SCID mice: a role for the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5. , 1996, Leukemia & lymphoma.

[52]  Jie Tian,et al.  Spectrally resolved bioluminescence tomography with the third-order simplified spherical harmonics approximation. , 2009, Physics in medicine and biology.